Piedmont Chemical

Revision as of 05:57, 4 July 2022 by Mythopoeia (talk | contribs) (Created page with "{{Infobox company | name = Piedmont Chemical | logo = 150px | type = {{wp|Public company|Public}} | traded_as = PPST:PC | ISIN = | founder = ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Piedmont Chemical
Public
Traded asPPST:PC
IndustryPharmaceutical
Chemical
FounderHeiner Knoerr (1838–1911)
Ian Uhlmann (1846–1906)

Piedmont Chemical (Vespasian: Piemonte Chimica) formerly known as the Standard Chemical (Vespasian: Chimico Standard) is an Adamantine multinational chemical and pharmaceutical corporation headquartered in Casamassella, San Loreto. The company was established in 1891 in Porto Pellegrini by two Weranian immigrants, Heiner Knoerr (1838–1911) and Ian Uhlmann (1846–1906). It has regional offices and production sites in Gaullica, Shangea and Marchenia.

Piedmont Chemical develops and produces an array of medicines, vaccines and industrial chemicals. Piedmont is best known for its development of Aspirina (acetylsalicylic acid) (1890), Insulina (insulin lispro) (1994) and Lucida (chlorpromazine) (1949). Piedmont's initial financial success was from its production of bleach and potassium bromide in the 1890s. During the Great War it mass produced key components for mustard gas, including potassium sulfide and 2-chloroethanol. It was among the first companies to mass-produce the polio vaccine, and has been a leading developer and producer of antipsychotics, antidepressants and synthetic opioids. Piedmont has several medications that individually generate more than ADM$1 billion in annual revenues.

Piedmont is a component of the Piedmont Cato Industrial Average (PCIA) and is publicly traded on the Porto Pellegrini Stock Exchange (PPST) and several of its chemical commodities are sold on the Porto Pellegrini Board of Trade (PPBT). The company is the second largest corporation by operating income, and the first in revenue in Adamantina. In 2020, 18% of the company's revenues came from Adamantina, 15% from nations in Asteria Inferior, 26% from Asteria Superior and 41% from Coius and Euclea.

History

Collaborative research

Public-private engagement

Products

Pharmaceutical

Chemical

Leadership

Controversies